Welcome to our dedicated page for Intuitive Surgical SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intuitive Surgical, Inc. (ISRG) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer headquartered in Sunnyvale, California, Intuitive uses these filings to report financial results, material events, and other information relevant to shareholders and regulators.
Among the key documents available are current reports on Form 8-K. Recent 8-K filings include items reporting quarterly financial results under Item 2.02, where Intuitive furnishes press releases detailing revenue, procedure growth on its da Vinci surgical systems and Ion endoluminal system, and changes in the installed base of systems. Another 8-K filing reports a change in the role of a senior executive under Item 5.02, illustrating how the company discloses updates related to its leadership structure.
Investors also use Intuitive’s SEC filings to follow information that may appear in annual reports on Form 10-K and quarterly reports on Form 10-Q, such as risk factor discussions, descriptions of the company’s business and technologies, and summaries of regulatory and market conditions affecting robotic-assisted surgery and minimally invasive care. While these specific forms are not reproduced in the provided excerpts, they are part of the broader filing set accessible through the SEC’s EDGAR system.
On Stock Titan, ISRG filings are paired with AI-powered summaries designed to explain the content and context of complex documents. These tools can help readers understand the significance of earnings releases, regulatory updates, or governance changes without reading every line of each filing. Users can also review filings that relate to financial reporting, such as exhibits containing press releases, and monitor how Intuitive communicates procedure trends, system placements, and other operational metrics to the market.
For investors researching Intuitive’s regulatory history, this page serves as a focused entry point to the company’s SEC disclosures, including 8-Ks that reference earnings announcements and other material developments.
Mark Brosius reported insider sales under 10b5-1 plans and listed planned dispositions of equity awards. The excerpt shows three 10b5-1 sales in December 2025: 4,500, 464, and 312 shares, with proceeds of $2,463,120.00, $254,499.36, and $170,776.32 respectively. It also lists 2,154 Restricted Stock Units dated 02/10/2026 and 1,173 Performance Stock Units dated 02/28/2026 as securities to be sold.
Notice of proposed resale under Rule 144 for ISRG securities. The filing lists recent transactions by Fredrik Widman: sale of 249 common shares on 02/27/2026 for $124,427.79 and sale of 133 common shares on 02/11/2026 for $65,829.68. The form also lists restricted common stock associated with an issuer entry dated 02/28/2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 for ISRG reporting proposed sales of 505 restricted stock and 4,223 performance shares dated 02/28/2026. The filing lists multiple recent open-market sales by Myriam Curet McAdams, including 2,345 shares on 02/27/2026 ($1,171,819.95) and 421 shares on 02/11/2026 ($208,378.16).
Intuitive Surgical executive Iman Jeddi, SVP & GM da Vinci Platforms, reported the vesting and settlement of equity awards. Performance stock units granted in 2023 and restricted stock units granted in 2022 were converted into common shares, with portions of the resulting stock (311 and 4,155 shares at $503.51) withheld to cover tax obligations rather than sold in the open market. Following these transactions, Jeddi holds common stock directly and indirectly through a trust.
Intuitive Surgical director Gary S. Guthart reported multiple equity award transactions in company stock. On February 28, 2026, he exercised 26,334 performance stock units and 2,506 restricted stock units, which converted into an equal number of common shares at no exercise price.
To satisfy statutory tax withholding on these settlements, 1,243 shares and 13,059 shares of common stock were disposed of at $503.51 per share, described as share withholding rather than open-market selling. Following these transactions, Guthart continued to hold common stock directly and also indirectly through several trusts for family members.
INTUITIVE SURGICAL INC executive Jamie Samath, EVP & CFO & Enterprise Technol, reported equity award activity involving performance and restricted stock units. On February 28, 2026, 10,773 performance stock units and 752 restricted stock units were converted into common stock following achievement of performance criteria and scheduled vesting. To satisfy statutory tax withholding obligations tied to these vestings, 373 and 5,343 common shares, respectively, were withheld at a price of $503.51 per share, with the remaining net shares delivered into the holder’s account.
Intuitive Surgical executive Gary Loeb exercised performance stock units and had shares withheld for taxes. On February 28, 2026, he converted 3,148 performance stock units granted on February 28, 2023 into 3,148 shares of common stock at $0.0000 per share, following achievement of required performance criteria.
The performance stock units vest on February 28, 2026, the third anniversary of the grant date, subject to his continuous service. In connection with this settlement, 1,562 common shares were withheld at $503.5100 per share to cover applicable taxes, leaving him with 6,520 directly owned common shares.
Intuitive Surgical EVP Henry L. Charlton reported multiple equity award settlements in the form of stock unit conversions and tax withholdings. On February 28, 2026, 10,773 performance stock units and 752 restricted stock units converted into common stock at no exercise price. A total of 335 and 4,800 common shares were withheld at $503.51 per share to cover statutory tax obligations related to these vestings. RSUs vest 25% per year over four years, while the reported PSUs vest on February 28, 2026 after performance criteria were achieved. Following these transactions, Charlton directly owned 11,610 shares of common stock.
Intuitive Surgical, Inc. has completed its acquisition of the da Vinci and Ion distribution business operated by ab medica, Abex, Excelencia Robótica, and their affiliates. This move shifts Intuitive to direct commercial operations in Italy, Spain, Portugal, Malta, San Marino, and associated territories.
The acquired business is now wholly owned and integrated into Intuitive’s European commercial and marketing organization, led by Senior Vice President and General Manager Dirk Barten. Approximately 250 employees are joining Intuitive as part of this expansion.
There were more than 470 da Vinci surgical systems installed in Italy, Spain, and Portugal as of December 31, 2025, providing an established base for Intuitive’s expanded direct presence in minimally invasive and robotic-assisted surgery in Southern Europe.
Intuitive Surgical CEO David J. Rosa reported multiple equity transactions on February 28, 2026 tied to vesting of performance and restricted stock units. He exercised or converted derivative awards into common stock, including 14,363 and 9,052 performance stock units from 2023 grants and 1,503 restricted stock units, each on a one-for-one basis into common shares.
To satisfy statutory tax withholding on these settlements, the company withheld shares classified as dispositions under code F, including 7,122, 4,489, and 746 common shares at a price of $503.51 per share. After these exercises and tax-withholding dispositions, Rosa directly owned 245,209 shares of Intuitive Surgical common stock.